Newsletter | October 11, 2021

10.11.21 -- Companies To Watch: Atea Pharmaceuticals

Exclusive Articles
Do You Anticipate Attending The Annual J.P. Morgan Healthcare Conference In Person In January 2022?

See the answer from Pamela Reilly Contag, Ph.D., the CEO and president of BioEclipse Therapeutics.

Companies To Watch: Atea Pharmaceuticals

Atea Pharmaceuticals is creating new nucleotide antivirals, including one the company is jointly developing with Roche to fight COVID-19.

How Quality Management Science Can Build A 5-Star Company

The following four concepts, based on the science of quality management, may serve to shift your mindset while you are considering how to define the company or organization that you, as the leader, deem five-star worthy.

Web-Exclusive Content
6 Key Steps For Cell Therapy Clinical Development Success

While the simplest option for a small or emerging biotech is to outsource protocol and clinical development to a consultant or CRO, a disengaged or absent sponsor is unlikely to have its objectives realized. Prior to engaging with a consultant or CRO, you can take these six steps that are likely to leave both parties engaged in the clinical development process.

Is Decentralized Manufacturing The Future Of Cell Therapy Manufacturing?
In this executive virtual roundtable (EVR) component, Bryan Butman, Ph.D., head of chemistry, manufacturing, and controls (CMC), Precigen, discusses the centralized approach to cell therapy manufacturing, along with his company’s approach of reducing dependence on the cold chain by implementing a decentralized manufacturing approach.
October 2021 Digital Edition

Inside you will find more on:

  • Preparing For Remote Inspections
  • Exclusive CEO Interviews
  • Financial Topics
  • Leadership Tips

View the digital edition.

Contribute To Life Science Leader
Article Submission Guidelines

Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.